New developments in the pharmacological treatment of chronic heart failure

Bibliography

• RICH MW, BECKHAM V, WITTENBERG C et al: A multidisciplinary intervention to prevent the readmission of elderly patients with congestive heart failure. N Engl. I Med. (1995) 333:1190–1195.
   PubMed Web of Science ®Google Scholar
• STEWART S, PEARSON S, HOROWITZ JD: Effects of a home-based intervention among congestive heart failure patients discharged from acute hospital care. Arch. Intern. Med. (1998) 158:1067–1072.
   PubMed Web of Science ®Google Scholar
• DOUGHTY RN, WRIGHT SP, WALSH HJ et al.: Randomised, controlled trial of integrated heart failure management: The Auckland Heart Failure Management Study. Ear: Heart J. (2002) 23:139–146.
   PubMed Web of Science ®Google Scholar
• BLUE L, STRONG E, DAVIE AP et al: Randomised controlled of specialist nurse intervention in heart failure. Br. Med. J. (2001) 323:715–718.
   PubMed Web of Science ®Google Scholar
• STEWART S, HOROWITZ JD: Home-based intervention in congestive heart failure: long-term implications on readmission and survival. Circulation (2002) 105:2861–2866.
   PubMed Web of Science ®Google Scholar
• BRADLEY DJ, BRADLEY EA, BAUGHMAN KL et al.: Cardiac resynchronization and death from progressive heart failure: a meta-analysis of randomized controlled trials. JA/VIA (2003) 289:730–740.
   Web of Science ®Google Scholar
• COOKLIN M: Devices for the management of ventricular arrhythmias in cardiac failure. Heart Fail. Rev (2002) 7:301–310.
   PubMedGoogle Scholar
• NADAL-GINARD B, KAJSTURA J, LERI A, ANVERSA P: Myocyte death, growth, and regeneration in cardiac hypertrophy and failure. Circ. Res. (2003) 92:139–150.
   PubMed Web of Science ®Google Scholar
• MENASCHE P: Cell therapy of heart failure. C. R. Biol. (2002) 325:731–738.
   PubMed Web of Science ®Google Scholar
• CLELAND JG, COHEN-SOLAL A, AGUILAR JC et al: Management of heart failure in primary care (the IMPROVEMENT of Heart Failure Programme): an international survey. Lancet (2002) 360:1631–1639.
   PubMed Web of Science ®Google Scholar
• •An important worldwide survey of current treatment practices for CHE
   Google Scholar
• POOLE-WILSON PA, CLELAND JG, DI LENARDA A et al.: Rationale and design of the carvedilol or metoprolol European trial in patients with chronic heart failure: COMET. Eur: J. Heart Fail (2002) 4:321–329.
   Google Scholar
• REMME WJ: Carvedilol ACE Inhibitor Remodelling Mild CHF EvaluatioN trial (CARMEN). XXIVth Congress of the European Society of Cardiology Berlin, Germany (2002) (Abstract).
   Google Scholar
• SHIBATA MC, FLATHER MD, BOHM M et al.: Study of the Effects of Nebivolol Intervention on Outcomes and Rehospitalisation in Seniors with Heart Failure (SENIORS). Rationale and design. Intl Cardiol. (2002) 86:77–85.
   PubMed Web of Science ®Google Scholar
• CLELAND JG, TENDERA M, ADAMUS J et al.: Perindopril for elderly people with chronic heart failure: the PEP-CHF study. The PEP investigators. Eur: Heart Fail. (1999) 1:211–217.
   PubMed Web of Science ®Google Scholar
• SWEDBERG K, PFEFFER M, GRANGER C et al: Candesartan in heart failure-assessment of reduction in mortality and morbidity (CHARM): rationale and design. Charm-Programme Investigators. J. Card. Fail (1999) 5:276–282.
   PubMedGoogle Scholar
• CARSON P: Irbesartan in Heart Failure with Preserved Systolic Function Berlin (I-PRESERVE). XXIVth Congress of the European Society of Cardiology Berlin, Germany (2002) (Abstract).
   Google Scholar
• •Ref [14–16]: First trials to specifically examine drug therapy for isolated diastolic heart failure.
   Google Scholar
• PITT B, SEGAL R, MARTINEZ FA et al:Randomised trial of losartan versus captopril in patients over 65 with heart failure. Evaluation of Losartan in the Elderly Study, ELITE. Lancet (1997) 349:747–752.
   Google Scholar
• PITT B, POOLE-WILSON PA, SEGAL R et al.: Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: Randomised trial - the Losartan Heart Failure Survival Study (ELITE II). Lancet (2000) 355:1582–1587.
   PubMed Web of Science ®Google Scholar
• COHN JN, TOGNONI G: Effect of the angiotensin receptor blocker valsartan on morbidity and mortality in heart failure: the Valsartan Heart Failure Trial (Val-HeFT). American Heart Association Scientific Sessions, New Orleans, USA (2000) (Abstract).
   Google Scholar
• MAGGIONI AP, ANAND I, GOTTLIEB SO, LATINI R, TOGNONI G, COHN JN: Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors. Am. Coll Cardiol (2002) 40:1414–1421.
   PubMed Web of Science ®Google Scholar
• PFEFFER MA, MCMURRAY J, LEIZOROVICZ A et al.: Valsartan in acute myocardial infarction trial (VALIANT): rationale and design. Am. Heart J. (2000) 140:727–750.
   PubMed Web of Science ®Google Scholar
• ROCHA R, WILLIAMS GH: Rationale forthe use of aldosterone antagonists in congestive heart failure. Drugs (2002) 62:723–731.
   PubMed Web of Science ®Google Scholar
• PITT B, ZANNAD F, REMME WJ et al: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl. J. Med. (1999) 341:709–717.
   PubMed Web of Science ®Google Scholar
• •Landmark study of the use of spironolactone in advanced CHF.
   Google Scholar
• PITT B, WILLIAMS G, REMME W et al.: The EPHESUS trial: eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction. Eplerenone Post-AMI Heart Failure Efficacy and Survival Study. Cardiovasc. Drugs Ther: (2001) 15:79–87.
   PubMed Web of Science ®Google Scholar
• ••Major clinical trial of the use of eplerenonein CHF, results of which are soon to be released.
   Google Scholar
• PACKER M, CALIFF RM, KONSTAM MA et al.: Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE). Circulation (2002) 106:920–926.
   PubMed Web of Science ®Google Scholar
• •Definitive clinical trial of omapatrilat in CHE
   Google Scholar
• KRUM H, DENVER R, TZANIDIS A, MARTIN P: Diagnostic and therapeutic potential of the endothelin system in patients with chronic heart failure. Heart Fail. Rev (2001) 6:341–352.
   PubMedGoogle Scholar
• GREENBERG BH: Endothelin and endothelin receptor antagonists in heart failure. Congest. Heart Fail. (2002) 8:257–261.
   PubMedGoogle Scholar
• HURLIMANN D, ENSELEIT F, NOLL G, LUSCHER TF, RUSCHITZKA F: Endothelin antagonists and heart failure. Curr. Hypertens. Rep. (2002) 4:85–92.
   PubMed Web of Science ®Google Scholar
• MCMURRAY JJ, RAY SG, ABDULLAH I et al.: Plasma endothelin in chronic heart failure. Circulation (1992) 85:1374–1379.
   PubMed Web of Science ®Google Scholar
• OMLAND T, LIE RT, AAKVAAG A et al.: Plasma endothelin determination as a prognostic indicator of 1-year mortality after acute myocardial infarction. Circulation (1994) 89:1573–1579.
   PubMed Web of Science ®Google Scholar
• PACKER M, CASPI A, CHARLTON V et al.: Multicenter, double-blind placebo-controlled study of long-term endothelin blockade with bosentan in chronic heart failure-results of the REACH-1 trial. Circulation (1998) 98 (Suppl. S):12.
   Google Scholar
• PACKER M: Endothelin Antagonist Bosentan for Lowering Cardiac Events in Heart Failure [ENABLE] 1 and 2. American College of Cardiology 51st Annual Scientific Session, Atlanta, GA, USA (2002) (Abstract).
   Google Scholar
• •Definitive clinical trial of bosentan in CHE
   Google Scholar
• ABRAHAM WT: Enrasentan Cooperative Randomized Evaluation (ENCOR). American College of Cardiology 50th Annual Scientific Session, Orlando, USA (2001) (Abstract).
   Google Scholar
• INAND IS, LUSCHER T: Endothelin Receptor Antagonist Trial in Heart Failure (EARTH). XXIVth Congress of the European Society of Cardiology Berlin, Germany (2002) (Abstract).
   Google Scholar
• TORRE-AMIONE G, VOOLETICH MT, FARMER JA: Role of tumour necrosis factor-alpha in the progression of heart failure: therapeutic implications. Drugs (2000) 59:745–751.
   PubMed Web of Science ®Google Scholar
• BERRY C, MCMURRAY JJ: Elevated serum and monocyte tumour necrosis factor alpha in patients with congestive heart failure. Intl Cardiol. (1999) 71:263–264.
   PubMed Web of Science ®Google Scholar
• BRYANT D, BECKER L, RICHARDSON J et al.: Cardiac failure in transgenic mice with myocardial expression of tumour necrosis factor alpha. Circulation (1998) 97:1375–1381.
   PubMed Web of Science ®Google Scholar
• MCMURRAY J, PFEFFER MA: New therapeutic options in congestive heart failure: Part II. Circulation (2002) 105:2223–2228.
   PubMed Web of Science ®Google Scholar
• •Second of excellent two-part review of new therapeutic options for CHE
   Google Scholar
• SCHRIER RW, BERL T, ANDERSON RJ:Osmotic and nonosmotic control of vasopressin release. Am. J Physiol. (1979) 236:F321–F332.
   PubMed Web of Science ®Google Scholar
• FUKUZAWA J, HANEDA T, KIKUCHI K: Arginine vasopressin increases the rate of protein synthesis in isolated perfused adult rat heart via the V1 receptor. Mol. Cell. Biochem. (1999) 195:93–98.
   PubMed Web of Science ®Google Scholar
• SZATALOWICZ VL, ARNOLD PE, CHAIMOVITZ C, BICHET D, SCHRIER RW: Radioimmunoassay of plasma arginine vasopressin in hyponatremic patients with congestive heart failure. New Eng] J Med. (1981) 305:263–266.
   PubMed Web of Science ®Google Scholar
• FRANCIS GS, BENEDICT C, JOHNSTONE DE et al.: Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation (1990) 82:1724–1729.
   PubMed Web of Science ®Google Scholar
• ROULEAU JL, PACKER M, MOYE L et al.: Prognostic value of neurohumoral activation in patients with an acute myocardial infarction: effect of captopril. J. Am. Coll Cardiol. (1994) 24:583–591.
   PubMed Web of Science ®Google Scholar
• MULINARI RA, GAVRAS I, WANG YX et al.: Effects of vasopressin antagonist with combined antipressor and antidiuretic activities in rats with left ventricular dysfunction. Circulation (1990) 81:308–311.
   PubMed Web of Science ®Google Scholar
• YATSU T, TOMURA Y, TAHARA A et al:Cardiovascular and renal effects of conivaptan hydrochloride (YM087), a vasopressin ViA and V2 receptor antagonist. Eur. J Pharmacol. (1999) 376:239–246.
   PubMed Web of Science ®Google Scholar
• NAITOH M, RISVANIS J, BALDING LC, JOHNSTON CI, BURRELL LM: Neurohumoral antagonism in heart failure; beneficial effects of vasopressin Via and V2 receptor blockade and ACE inhibition. Cardiovasc. Res. (2002) 54:51–57.
   PubMed Web of Science ®Google Scholar
• UDELSON JE, SMITH WB, HENDRIX GH et al.: Acute hemodynamic effects of conivaptan, a dual ViA and V2 receptor antagonist, in patients with advanced heart failure. Circulation (2001) 104:2417–2423.
   PubMed Web of Science ®Google Scholar
• TANNER H, MOSCHOVITIS G, KUSTER GM et al.: The prevalence of anemia in chronic heart failure. Lit. J Cardiol. (2002) 86:115–121.
   Web of Science ®Google Scholar
• SILVERBERG DS, WEXLER D, BLUM M et al.: The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations. J. Am. Coll Cardiol. (2000) 35:1737–1744.
   PubMed Web of Science ®Google Scholar
• SILVERBERG DS, WEXLER D, SHEPS D et al: The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study. J Am. Coll Cardiol. (2001) 37:1775–1780.
   PubMed Web of Science ®Google Scholar
• MANCINI DM, KATZ SD, LANG CC et al.: Effect of erythropoietin on exercise capacity in patients with moderate to severe chronic heart failure. Circulation (2003) 107:294–299.
   PubMed Web of Science ®Google Scholar
• ZARAIN-HERZBERG A, RUPP H: Transcriptional modulators targeted at fuel metabolism of hypertrophied heart. Jim. Cardiol. (1999) 83:31H–37H.
   Google Scholar
• FELDMAN AM, LI YY, MCTIERNAN CF: Matrix metalloproteinases in pathophysiology and treatment of heart failure. Lancet (2001) 357:654–655.
   PubMed Web of Science ®Google Scholar
• PETERSON JT, HALLAK H, JOHNSON L et al: Matrix metalloproteinase inhibition attenuates left ventricular remodeling and dysfunction in a rat model of progressive heart failure. Circulation (2001) 103:2303–2309.
   PubMed Web of Science ®Google Scholar
• CHANCEY AL, BROWER GL, PETERSON JT, JANICKI JS: Effects of matrix metalloproteinase inhibition on ventricular remodeling due to volume overload. Circulation (2002) 105:1983–1988.
   PubMed Web of Science ®Google Scholar
• ARONSON D: Cross-linking of glycated collagen in the pathogenesis of arterial and myocardial stiffening of aging and diabetes. J Hypertens. (2003) 21:3–12.
   PubMed Web of Science ®Google Scholar
• PITT B, REMME W, ZANNAD F et al.: Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Eng]. J Med. (2003) 348:1309–1321.
   PubMed Web of Science ®Google Scholar